Literature DB >> 28988381

Response to the letter from Dr. Veerman and colleagues.

Taro Kishi1, Toshikazu Ikuta2, Yuki Matsuda3,4, Nakao Iwata3.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28988381     DOI： 10.1007/s00213-017-4757-8

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN： 0033-3158            Impact factor:   4.530


× No keyword cloud information.
  6 in total

1.  Adjunctive memantine in clozapine-treated refractory schizophrenia: an open-label 1-year extension study.

Authors:  S R T Veerman; P F J Schulte; J B Deijen; L de Haan
Journal:  Psychol Med       Date:  2016-10-25       Impact factor: 7.723

Review 2.  Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.

Authors:  Y Iwata; S Nakajima; T Suzuki; R S E Keefe; E Plitman; J K Chung; F Caravaggio; M Mimura; A Graff-Guerrero; H Uchida
Journal:  Mol Psychiatry       Date:  2015-06-16       Impact factor: 15.992

Review 3.  Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Authors:  Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2004-09-01       Impact factor: 13.382

Review 4.  Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy.

Authors:  Kee-Hong Choi; Til Wykes; Matthew M Kurtz
Journal:  Br J Psychiatry       Date:  2013-09       Impact factor: 9.319

5.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21

6.  Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.

Authors:  S R T Veerman; P F J Schulte; J D Smith; L de Haan
Journal:  Psychol Med       Date:  2016-04-06       Impact factor: 7.723
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.